Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05683379 · ClinicalTrials.gov registry record
AFFINITY BEYOND: Anti-AAV8 Antibody Assessment Study of Males With DMD
A clinical trial of Duchenne Muscular Dystrophy, sponsored by REGENXBIO.
- Recruiting
- Registry status
- 200
- Enrollment target
- 1
- Study location
NCT05683379: Recruiting study of Duchenne Muscular Dystrophy, sponsored by REGENXBIO.
NCT05683379 is a study of Duchenne Muscular Dystrophy that is actively recruiting participants, run by REGENXBIO. The registered enrollment target is 200 participants, below the 408-participant average among 48 other Duchenne Muscular Dystrophy trials with a reported enrollment target (51% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05683379, a study of Duchenne Muscular Dystrophy, is actively recruiting participants, sponsored by REGENXBIO.
- RECRUITING
- Registry status
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an observational screening study to evaluate the prevalence of anti-adeno-associated serotype 8 (AAV8) antibodies in participants with Duchenne muscular dystrophy (DMD).
Primary Outcome
* To evaluate the prevalence of AAV8 antibodies in patients with DMD * To identify participants who may be eligible for investigational gene therapy clinical trials in males with DMD
Conditions Studied
Interventions
- DIAGNOSTIC_TEST AAV8 DetectCDx
Study Locations (1)
Georgia
- Rare Disease Research - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2022-12-20 |
| Est. Completion | 2026-09 |
What NCT05683379 shows while recruiting
NCT05683379 is an observational study that tracks outcomes without assigning an intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 408-participant average among 48 other Duchenne Muscular Dystrophy trials with a reported enrollment target (51% lower).
The record links to 1 condition, with Duchenne Muscular Dystrophy appearing as the primary indexed condition, and to 1 intervention - of which AAV8 DetectCDx is the first listed.
NCT05683379 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT05683379 about?
NCT05683379 is a clinical study titled "AFFINITY BEYOND: Anti-AAV8 Antibody Assessment Study of Males With DMD". This is an observational screening study to evaluate the prevalence of anti-adeno-associated serotype 8 (AAV8) antibodies in participants with Duchenne muscular dystrophy (DMD).
What is the current status of trial NCT05683379?
This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2022-12-20. Estimated completion is 2026-09.
What conditions does trial NCT05683379 study?
This clinical trial studies the following conditions: Duchenne Muscular Dystrophy.
What interventions are being tested in trial NCT05683379?
The interventions under investigation include: AAV8 DetectCDx (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05683379?
This trial is sponsored by REGENXBIO, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05683379 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Duchenne Muscular Dystrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05683379's enrollment target sits among peer trials
200 9th of 48 higher than 40 of 48 other Duchenne Muscular Dystrophy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Duchenne Muscular Dystrophy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
RECRUITING · Phase 1
-
AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD)
RECRUITING · Phase 2
-
Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients
RECRUITING · Phase 2
-
Once Weekly Infant Corticosteroid Trial for DMD
RECRUITING · Phase 4
-
The Duchenne Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI